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2Abstract
Cardiac failure is a common complication in cancer survivors treated with anthracyclines. 
Here we followed up cardiac function and excitation-contraction (EC) coupling in an in 
vivo doxorubicin (Dox) treated mice model (iv, total dose of 10 mg/Kg divided once every 
three days). Cardiac function was evaluated by echocardiography at 2, 6 and 15 weeks 
after the last injection. While normal at 2 and 6 weeks, ejection fraction was significantly 
reduced at 15 weeks. In order to evaluate the underlying mechanisms, we measured 
[Ca2+]i transients by confocal microscopy and action potentials (AP) by patch-clamp 
technique in cardiomyocytes isolated at these times. Three phases were observed: 1/ 
depression and slowing of the [Ca2+]i transients at 2 weeks after treatment, with 
occurrence of proarrhythmogenic Ca2+ waves, 2/ compensatory state at 6 weeks, and 3/ 
depression on [Ca2+]i transients and cell contraction at 15 weeks, concomitant with in-
vivo defects. These [Ca2+]i transient alterations were observed without cellular 
hypertrophy or AP prolongation and mirrored the sarcoplasmic reticulum (SR) Ca2+ load 
variations. At the molecular level, this was associated with a decrease in the 
sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) expression and enhanced RyR2 
phosphorylation at the protein kinase A (PKA, pS2808) site (2 and 15 weeks). RyR2 
phosphorylation at the Ca2+/calmodulin dependent protein kinase II (CaMKII, pS2814) 
site was enhanced only at 2 weeks, coinciding with the higher incidence of 
proarrhythmogenic Ca2+ waves. Our study highlighted, for the first time, the progression 
of Dox treatment-induced alterations in Ca2+ handling and identified key components of 
the underlying Dox cardiotoxicity. These findings should be helpful to understand the 
early-, intermediate-, and late- cardiotoxicity already recorded in clinic in order to prevent 
or treat at the subclinical level.
3Introduction
Cardiovascular diseases are the main death cause in the world, accounting up to 48% of 
non-communicable diseases, followed by cancer at 21% [1]. Early detection and 
efficacious management of anticancer therapies have enhanced long term survival rates 
following cancer. However, cardiovascular complications account for up to 33% of 
mortality cause in cancer survivors [2]. Thus cardiotoxicity is a major concern of 
anticancer therapies [3-6]. On top of the acute side effects, some toxicities manifest 
later, sometimes years after ending the therapy, hampering the patient quality of life or 
even their life expectancy. Notably, heart failure (HF) occurs more frequently in patients 
treated with anthracyclines, whose lead compound is doxorubicin (Dox), compared to 
any other anticancer therapies, placing anthracyclines as the main cardiotoxic drugs [5]. 
Different proposed mechanisms such as oxidative stress and cell death have been 
invoked. Antioxidants have been used in an attempt to prevent cardiotoxic effects, but 
with poor results or even detrimental effects [7, 8]. However, Ca2+ homeostasis 
deregulation could be also of particular importance in the development of Dox-induced 
cardiotoxicity due to its key role in cardiac functions, such as electrical activity, 
excitation-contraction (EC) coupling, and excitation-transcription coupling [9]. It is thus 
important to elucidate the underlying mechanisms of cardiac side effects in order to 
prevent or limit the cardiotoxic manifestations. 
Ca2+ handling has been shown to be altered in HF of other etiologies. Most of the HF 
models, including human samples, have shown a general depression of the efficacy of 
the Ca2+ -induced Ca2+ release mechanism, characterized by the maintenance of the L-
type Ca2+ current density, and depressed [Ca2+]i transients, together with a prolongation 
of the action potential (AP) duration [10]. Nevertheless, depressed contractile function in 
HF of different etiologies may reflect different mechanisms. For instance, while 
hypertension and myocardial infarction induce the alterations cited above [11-13], 
4diabetes-induced cardiac dysfunction [14], and myocardial infarction in the rabbit [15] 
include a reduction in the L-type Ca2+ current density. Thus, Dox-induced HF may or 
may not share some alterations with HF of other etiologies. 
No much information is known about Ca2+ handling in Dox-induced cardiac dysfunction. 
Moreover, as HF evolves with time, it is important to get information at different time 
points, in order to get hints into the progression of Dox cardiotoxicity. While there are 
some data on acute effects of doxorubicin on EC coupling, very few analyses have 
addressed the question in Dox -induced cardiac dysfunction after chronic treatment [16]. 
Isolated cardiac myocytes perfused 30 minutes with Dox [17] showed increased Ca2+ 
sparks occurrence and decreased [Ca2+]i transients. These effects were attenuated, but 
not completely prevented, by Ca2+/calmodulin dependent protein kinase II 
(CaMKII) inactivation. Because Ca2+ sparks reflect ryanodine receptors type 2 (RyR2) 
openings [18], a direct effect of Dox on the RyR2 may also contribute to the acute 
effects. In fact, Dox can bind and exert a direct effect on the RyR2 enhancing its 
activity [19]. As a matter of fact, Dox and its metabolite doxorubicinol directly affects the 
RyR2, promoting
 an initial reversible open probability increase, which might contribute to the 
elevated Ca2+ sparks rate, following by its inhibition. In addition, recent data have also 
shown that the anthracycline metabolite doxorubicinol abolishes the RyR2 sensitivity to 
luminal Ca2+ by interacting with cardiac calsequestrin (CSQ2) favoring arrhythmic 
conditions [20]. While the Reactive Oxygen Species (ROS) effect might be prevented 
by antioxidants, the direct effect on RyR2 could not [21, 22]. Besides these acute 
effects, some cardiac dysfunctions may appear even years after the end of 
chemotherapy [7], with progressive 
5decrease in the contractile function (measured as ejection fraction) that may lead to 
irreversible HF [23]. Once clinical signs of HF appeared, the patients are treated as any 
HF patient with other etiologies, including inhibitors of angiotensin-renin-aldosterone 
system and  [3, 6]. However, the cellular and molecular mechanisms as well 
as the progression of the alterations involved in Dox-induced cardiotoxicity are not 
completely understood.
In the present study, we have performed, for the first time, a complete analysis of the 
cardiac function by echocardiography in vivo and by [Ca2+]i dynamic analysis in 
cardiomyocytes ex vivo at different times (2, 6 and 15 weeks) after chronic low dose Dox 
treatment in mice. In parallel, we have investigated the underlying molecular 
mechanisms. We showed an initial depression in [Ca2+]i transient amplitudes, at 2 weeks 
after the end of the treatment, that was then compensated at 6 weeks. However, 15 
weeks after the end of the treatment, cardiac function was impaired with a reduction of 
ejection fraction and slight dilation that was correlated with a depression in the [Ca2+]i
transients. These 3 phases could be explained at the molecular level by RyR2, 
SarcoEndoplasmic Reticulum Ca2+ ATPase (SERCA2a) and phospholamban (PLB) 
alterations. We thus conclude that intracellular Ca2+ alterations precede over cardiac 
dysfunction in Dox-induced cardiotoxicity without structural alterations (fibrosis and 
myofibril loss).
2. Material and Methods
2.1 Doxorubicin treated mice
All experiments were carried out according to the ethical principles laid down by the 
French and European Union Council Directives for the care of laboratory animals 
86/609/ECC. Twelve-week old C57BL/6 male mice received 3 i.v. injections (3 days 
6interval) of doxorubicin (Dox) up to a total accumulated dose of 10.1±0.4 mg/kg. Control 
animals were injected likewise but with saline solution (NaCl 0.9%). Data were obtained 
at 2, 6 and 15 weeks after last i.v. injection. In total we obtained data from 54 mice for 
saline treatment and 64 for Dox treatment.
2.2 In vivo recordings 
Transthoracic echocardiography (Vivid 9, General Electric Healthcare, Piscataway, NJ) 
was performed the day previous cardiomyocyte isolation using a 15 MHz transducer 
under 3% isoflurane gas anesthesia. Two-dimensional-guided (2D) M-mode 
echocardiography was used to determine contractile parameters such as fractional 
shortening (FS) or ejection fraction (EF), and morphometric parameters. 
In vivo telemetric ECG recording was performed in awake free-moving mice, by 7 ETA-
F10 transmitters (DSI) implants as earlier [24]. ECG analyses were made by EMKA 
technologies (ECGAUTO).
2.3 Myocyte isolation
Ventricular cardiac myocytes were isolated from control and treated mice 2, 6 and 15 
weeks after last i.v. injection using a standard enzymatic digestion [25]. Cardiomyocyte 
morphometric parameters were analyzed by measuring the width, length, and surface 
area on imageJ pictures obtained from isolated cardiomyocytes. Parameters were 
determined in a blind manner by computer-assisted planimetry (Perkin Elmer). At least 
150 individualized cells per mice and 3-4 animals were analyzed for each condition.
2.4 Intracellular Ca2+ handling measurement
Intracellular calcium ([Ca2+]i) dynamics were recorded in intact ventricular myocytes 
loaded with fluorescence Ca2+ dye Fluo-3 AM (5 µM for 30 min at RT) with a confocal 
microscope (see below). To record [Ca2+]i transients, cells were electrically stimulated at 
72 Hz by field stimulation using two parallel platinum electrodes [25] while perfused with 
normal Tyrode solution (in mM): NaCl 140, KCl 4, HEPES 10, MgCl2 1.1, CaCl2 1.8, 
glucose 10; pH=7.4 with NaOH. Spontaneous Ca2+ sparks and waves were obtained in 
quiescent cells after field-stimulation recordings. In order to estimate Sarcoplasmic 
Reticulum (SR) Ca2+ content, cells were rapidly exposed to 10 mM caffeine just after 
field-stimulated at 2 Hz to allow for stable SR Ca2+ load. 
Images were obtained with a laser scanning confocal microscope (TCS SP5X Leica 
Microsystems) equipped with an x40/x63 water-immersion objective (N.A. 1.4-1.2) in the 
line scan mode (1.43 ms/line). The scanning line was selected parallel to the longitudinal 
cell axis to be able to measure cell shortening. Fluo-3 was excited with a White light 
laser tuned at 500 nm, and emission measured at wavelengths above 510 nm. Image 
analyses were performed by homemade routines running in IDL 8.2 software (Exelis 
Visual Information Solutions, Inc.). Images were corrected for the background of 
fluorescence. 
2.5 Immunoblotting
Mice left ventricles were lysed with RIPA lysis buffer containing protease and 
phosphatase inhibitors (Roche). Immunodetection by Western-blot was performed by 
electrophoresis of proteins (20 µg) in a 10%, 15% or 4-12% SDS-PAGE gel, followed by 
transfer to a PVDF membrane (GE Healthcare). Membranes were blocked with TBS-
Tween 0.1% - Milk 5% and incubated with primary antibodies for SERCA2a (Santa Cruz; 
1:1000), PLB (Santa Cruz; 1:500), phosphorylated PLB at Ser16 and Thr17 (Badrilla; 
1:2000), RyR2 (Pierce, 1:2000), phosphorylated RyR2 at Ser2814 and 2808 (Badrilla; 
1:2000) and NCX (Swant; 1:1000). Membranes were incubated with corresponding HRP 
secondary conjugated antibody (Santa Cruz; diluted at 1 10000 in TBST containing 5% 
8milk). Reactive proteins were visualized by chemiluminescence detection system 
(ChemiDocTM MP imaging system, Biorad). Incubation with  antibody (Santa Cruz 
Biotechnology, diluted at 1:30000) was performed to normalize the chemiluminescence 
levels and exposure times. The same pool of protein standards was added to the 
different WB in order to compare protein quantification along the 15 weeks of 
experimentations.  
2.6 Histological assessments
Hearts were fixed in 4% paraformaldehyde, embedded in paraffin and serial sectioned 
(3µm). Sections were stained with Picrosirius Red F3BA for interstitial collagen 
evaluation, or hematoxylin and eosine for global morphology and tissue inflammatory 
status.
Two to three sections per animal were examined at 20X and 40X magnification, 5-10 
fields per section were recorded with an AxioCam MRc camera (Carl Zeiss); analyses 
were realized with ImageJ software and conducted by two independent investigators. 
Collagen quantification was expressed as a percentage of total tissue.
2.7 Statistics
Experimental data are expressed as means ± S.E.M. Differences between groups at 
each time point have been analyzed by one-way ANOVA followed and unpaired 
Student’s t-test. Differences were considered statically significant when *p<0.05, 
**p<0.01, ***p<0.001.
3. Results
93.1 Depressed Cardiac Function 15 weeks after last Dox injection
We aimed to investigate whether Dox influences cardiac function after in vivo treatment. 
Age and weight matched male mice received 3 iv injections on alternate days up to a 
cumulative dose of 10 mg Dox. Functional characterization by M mode 
echocardiography was performed at 2, 6 and 15 weeks after the last injection. While 
cardiac function was normal at 2 and 6 weeks, it was significantly depressed 15 weeks 
after the last injection (Fig. 1A). Namely, the Ejection Fraction (Fig. 1B) and Fractional 
Shortening (Fig. 1C) were significantly depressed in Dox-treated animals, without 
alteration of the heart rate measured during echocardiography (573±40 bpm in 5 Saline 
mice vs. 542±36 in 7 Dox-treated animals).  Dox treatment produced a delay in weight 
gain during the first two weeks (Supplementary. Fig.S1A) but failed to induce cardiac 
hypertrophy as indicated by the ratio heart weight to tibia lengths (Supplementary Fig. 
S1B). Echocardiographic analyses showed slight dilation at 15 weeks after the last 
injection manifested by a significant increase in the End Diastolic Diameter (Fig. 1D). 
Lack of development of cardiac hypertrophy was evidenced at the cellular level by the 
absence of alteration of membrane capacitance (in pF: at 2 weeks 162.4±20.6 n=10 
Saline vs 157.9±12.5 n=10 Dox; at 6 weeks 179.5±13.9 n=19 Saline vs 175.2±17.2 n=19 
Dox; at 15 weeks 171.6±12.8 n=15 Saline, vs 218.5±22.4 n=5 Dox) or surface area (in 
µm2: at 2 weeks 3125.9±191.7 Saline vs. 3096.0±238.2 Dox; at 6 weeks 3009.5±211.8 
in Saline vs 2943.2±145.7 Dox; at 15 weeks 3454.7±176.0 Saline vs 3288.4±114.4 Dox). 
The decrease in contractile function at 15 weeks post treatment could be due to 
development of fibrosis, or to a defect on the cardiomyocyte contraction itself. We 
previously showed that cardiac fibrosis was involved in heart dysfunction after 
radiotherapy [26]. Thus we wanted to investigate whether this mechanism was also 
present after Dox treatment. No significant fibrosis (Figure 1E) or other structural 
alteration such as myofibrillar disorganization, or vacuolization (Supplemental Figure 
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S1C) in Dox treated animals were observed. These data suggests that the depressed 
contractile function may be dependent on impaired cardiomyocyte function.   
3.2 Dox treatment Differently Modulated [Ca2+]i transients over time
Since Ca2+ activates cell contraction, depressed contractile function at 15 weeks after 
Dox treatment, might be due to alterations of intracellular Ca2+ fluxes at cellular level. 
Figure 2A shows representative examples of line scan images taken from ventricular 
cardiac myocytes under field-stimulation at 2 Hz. Dox treatment had different effect over 
time after last i.v. injection, as summarized in Figure 2B and 2C for [Ca2+]i transients 
amplitude (F/F0) and constant of transient decay (Tau), respectively. Since we noticed a 
variation with age, each data in Dox-treated animals were normalized by the data in 
Saline-treated animals, thus matching age and time after last injection. [Ca2+]i transient 
amplitude (peak F/F0) was depressed at 2 weeks after Dox treatment (Figure 2B). 
However, this initial depression was overcome at 6 weeks, where there was even an 
increase in the [Ca2+]i transient amplitude. Over time and, consistent with the depressed 
cardiac function observed at 15 weeks after Dox treatment in vivo, we observed a 
significant decrease in the [Ca2+]i transient amplitude (Figure 2B) and slowing of its 
decay time (Fig. 2C). Unloaded cell shortening was significantly depressed only at 15 
weeks after last Dox injection (Fig. 2D). These data suggests that the depression in 
cardiac contraction 15 weeks after the last Dox injection, is at least in part, due to a 
depression in the [Ca2+]i transient amplitude. 
3.3 Dox treatment did not alter Action Potential Duration
As [Ca2+]i transients are triggered by action potentials, the differences on [Ca2+]i
transients might result from action potential (AP) alterations. As summarized and 
exemplified in the inset of Figure 3, no alterations were observed in AP duration at 20 
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(APD20%), 50 (APD50%) nor 90% repolarization (APD90%). Other AP parameters were 
neither affected by Dox-treatment, such as zero current potential nor AP amplitude (data 
not shown). These cellular data were consistent with no alteration of the QTc measured 
by telemetry in mice (in ms: 59.3±1.4 [n=7] in Saline vs 60.0±1. 8 in [n=6] Dox-treated 
mice at 2W and 68.0±2.0 [n=7] in saline vs 64.4±2.5 in [n=5] Dox treated mice at 6 
weeks). 
3.4 SR Ca2+ Load Reduced 15 weeks after last Dox injection
Since the (AP), which activates the trigger (ICa) is not altered, modifications in the [Ca2
+]i transient after Dox treatment might result from differences in the amount of Ca2+ 
stored in the SR. The SR Ca2+ load was estimated by caffeine-evoked [Ca2+]i 
transients. Cells were field-stimulated at 2 Hz allowing to achieve stable SR Ca2+ 
load, and then were rapidly exposed to 10 mM caffeine as exemplified with the line 
scan images in Figure 4A, after different times of last injection either with Saline 
(top) or Dox (bottom). The pattern of amplitudes of the caffeine-evoked [Ca2+]i 
transients at different times after the last Dox injection (Fig. 4B) paralleled the 
alterations in [Ca2+]i transients amplitudes, namely it was depressed at 15 weeks post 
Dox injection after a period of increase at 6 weeks. Thus alterations in the SR Ca2+ 
load could account for the decrease in the [Ca2+]i transients and contractions.
Altered expression or function of the proteins involved in Ca2+ release, uptake and/or 
extrusion such as SERCA2a, PLB, RyR2, and NCX might underlie the decreased SR 
Ca2+ load at 15 weeks. The decay phase of the electrically evoked [Ca2+]i transient in the 
mouse is mainly due to Ca2+ uptake into the SR by SERCA2a, and in a minor extension 
to extrusion through the NCX. Other slow systems account for about 1% [27]. As shown 
in Fig. 2C, the [Ca2+]i transient decay phase was slowed at 2 and 15 weeks after last 
Dox injection, suggesting that SERCA2a and/or NCX function or expression are 
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depressed at these time points. During caffeine application, the RyR2 are kept open, 
thus any Ca2+ pumped back by SERCA2a is immediately released through the open 
RyR2. Consequently the decay phase of the caffeine-evoked [Ca2+]i transient is mainly 
due to extrusion through NCX. No statistically significant difference at any time point 
after Dox treatment was observed either in the decay time constant of caffeine-evoked 
transients (Tau, Fig. 4C) or levels of NCX protein expression (Fig. 4D), suggesting that 
NCX function/expression is not significantly altered after Dox treatment.
We then addressed the SERCA2a expression in our Dox mice model. As shown in 
western blots examples (Fig. 5A) and averaged data of each animal group (Fig. 5B) and 
consistent with the [Ca2+]i transient decay slowing down (Fig. 2B), significant decreases 
in SERCA2a expression at 2 and 15 weeks were observed after Dox treatment, 
compared to the saline treated animals. In addition and showed in Figure 5 C through F, 
we observed that the total phospholamban levels were normal at 2 and 15 weeks, but 
reduced at 6 weeks after Dox treatment compared to Saline treated mice (Fig. 5D), 
without significant alteration of its phosphorylation at Ser16 (Fig. 5E) and at Thr17 (Fig. 
5F) at any analyzed time point following Dox treatment. This might be involved in the 
compensatory phase observed at 6 weeks. 
3.5 Spontaneous Ca2+ release in Dox-treated mice
In other models of HF, an increase in the diastolic Ca2+ leak explained by a high activity 
of RyRs has been invoked to account for reduced SR Ca2+ load. Analysis of the 
spontaneous Ca2+ sparks in quiescent cells, as exemplified in Figure 6A, shows an 
increase in Ca2+ sparks frequency at 2 and 15 weeks (Fig. 6B), coinciding with the time 
points of depressed [Ca2+]i transients and SR Ca2+ load. Western blots analyses showed 
that the level of RyR2 expression was transitorily depressed at 2 weeks after the last 
injection and normalized afterwards (Fig. 6C & D). This depression in RyR2 expression 
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could account to the initial decrease in the Ca2+ spark amplitude (Supplementary Fig. 
S2A). Other Ca2+ sparks characteristics were also differently regulated depending on the 
time after the last injection. Supplementary Fig. S2 B shows prolonged Ca2+ spark 
duration at 2 and 15 weeks, time at which SERCA2a level was depressed, and increase 
in width only at 15 weeks post Dox injection (Supplementary Fig. S2 C). RyR2 
phosphorylation level at the PKA site (S2808) was enhanced at 2 and 15 weeks (Fig. 
6C, E), coinciding with the periods of higher Ca2+ sparks frequency. Interestingly, RyR2 
phosphorylation at the S2814 site, which is identified as the CaMKII site, was enhanced 
only early after Dox treatment, at 2 weeks (Fig. 6C & F). In addition and in accordance 
with some reports showing that RyR2 phosphorylation at this site was 
proarrhythmogenic [28], spontaneous Ca2+ waves were enhanced at 2 weeks post 
treatment (Fig. 6G). 
Discussion
In summary, follow up of the anthracycline-induced cardiotoxicty in mice demonstrated a 
time dependent alteration in cardiac Ca2+ handling, which culminated to depressed 
cardiac function 15 weeks after the treatment without electrical, nor hypertrophic 
cardiomyocyte remodeling, nor myocardial fibrosis. We found that Dox treatment 
induced an initial increase in diastolic Ca2+ leak, which returned later to 
normal. However, 15 weeks after the treatment, the animals presented decreased 
ejection fraction. The latter can be at least in part explained by a depression in 
the [Ca2+]i transients due to reduction in SERCA expression. This Dox-induced 
calcium handling dysfunction occurred, as opposed to other heart failure models 
without hypertrophy development nor AP duration alteration.
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We have established a model of in-vivo Dox treatment by 3 i.v. Dox injections within 
therapeutic levels and without induction of animal death. A fractionated I.V. protocol with 
a total cumulated dose away from toxic values was chosen in an attempt to be closer to 
the clinical situation. Similar fractioning and cumulated doses has recently been 
published by other authors [29]. Echocardiographic data showed a significant depression 
in the ejection fraction and fractional shortening in Dox-treated mice compared to saline, 
only 15 weeks after the end of treatment. At that time, the cardiac myocytes unloaded 
contraction was reduced, and [Ca2+]i transients were significantly depressed and slowed. 
Although these alterations have been found in models of HF, these alterations appeared 
in the absence of cardiac remodeling, as neither the heart nor the myocytes were 
hypertrophied. Moreover, no significant fibrosis was detected. This is in contrast to our 
previous findings in radiotherapy-induced cardiac dysfunction, where depressed 
contractile heart function was associated with cardiac fibrosis whereas cellular [Ca2+]i 
transients were preserved [26]. The lack of fibrosis in our Dox model indicates that at the 
doses we used, the cardiac dysfunction is not dependent on myocytes cell death and 
structural alterations in a type I cardiotoxicity manner. This is also in agreement with the 
clinical observation of a partial or full heart function recovery for a large percentage of 
patients under Enalapril and -blockers treatment (11% and 71% of patients with full or 
partial recovery respectively) [6]; a phenomenon that would not have been possible if 
decreased cardiac function would only rely on cell death. 
Our results show that Ca2+ handling alteration is already evident 2 weeks after the last 
Dox injection, but was followed by a compensation phase, at 6 weeks, where neither the 
cardiac function, nor the [Ca2+]i handling was impaired. The [Ca2+]i transient was thus 
reduced in amplitude at 2 and 15 weeks post-treatment (Fig. 2), which may reflect 
the depression on SR Ca2+ content (Fig. 4). Strikingly, even if the [Ca2+]i transient 
was 
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reduced at two weeks, this was not translated into a significant decrease of the unloaded 
cell contraction, nor the echocardiographic functional parameters. This data 
suggests thus that Dox treatment could increase myofibrils Ca2+ sensitivity at early 
stage.  This hypothesis is supported by the finding that Dox has a positive inotropic 
effect by directly acting on contractile myofibrils [30].  While the increased Ca2+ leak 
through enhanced Ca2+ sparks occurrence (Fig. 6) may be involved in the decreased 
SR Ca2+ load, the depression in SR content can be related to the reduced SERCA 
expression at 2 and 15 weeks after the end of treatment (Fig. 5). In fact, reduction of 
SERCA function can be observed as the slowing of the [Ca2+]i transient at these 
time points. This result is consistent with the slowing of the [Ca2+]i transient in a rat 
model [31], which however showed alteration of the peak [Ca2+]i transient. In 
addition to the different doses and animal model used, the evolution of the disease 
may also account for the different effects on [Ca2+]i transient amplitude. 
Interestingly, during the compensatory phase (6 weeks), the PLB level was 
depressed (Fig. 5). Inhibitory effect of PLB over SERCA function is decreased, 
resulting in accelerated SR reloading (Fig. 4) and higher peak [Ca2+]i transient (Fig. 
2) at this time point. Our results echoed biochemical analyses during Dox treatment 
showing a decrease in both SERCA and PLB cardiac levels at 8 weeks [31-33]. 
However, SERCA may not be a target to limit cardiotoxic actions of Dox, since SERCA 
overexpressing mice have lower survival than WT after Dox treatment [34], 
suggesting that the initial SERCA depression may be a compensatory response.
At 2 and 15 weeks after the last injection, isolated cardiomyocytes showed an increased 
Ca2+ spark frequency (Fig. 6). This echoes the effect of short incubation of 
cardiac myocytes in the presence of Dox [17], but contrast with the reported 
depressed expression of RyR2 in a rabbit in vivo Dox treatment [33, 35]. At 2 weeks we 
denoted a decrease in RyR2 expression (Fig. 6) and in Ca2+ spark amplitude (supp. Fig. 
S2), which 
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was normalized later on. However, even at this time point, Ca2+ sparks were more 
frequent after Dox treatment (Fig. 6B). It has been shown that Dox directly affects RyR2 
activity by a rapid reversible activation of the channel and latter causes an irreversible 
inhibition [21, 22]. In our experimental model, Dox was administered in vivo and 
experiments were made several weeks after the end of the treatment. The direct effects 
would thus not be present anymore, as Dox pharmacokinetics after i.v. injection in mice 
are very fast and almost no present 24 hours after the injection [36]. The enhanced Ca2+ 
sparks frequency at 2 weeks could be accounted by different phosphorylation level of 
the RyR2 [17]. In fact, the relative RyR2 phosphorylation level was increased in both 
PKA and CaMKII sites at 2 weeks and only at the PKA site at 15 weeks after 
the treatment, coinciding with times of high Ca2+ sparks frequency (Fig. 6). An open 
question may be what is activating both PKA and CaMKII. Circulating catecholamines 
are often increased in order to compensate for an insult. This could lead to PKA 
activation and RyR2 phosphorylation. We can hypothesize, that close to the injections, 
in an attempt to increase the fight response, the heart is under adrenergic stimulation. 
Alternatively or additionally, activation of CaMKII and PKA could be related to the 
oxidant properties of Dox, which has been also shown to be able to activate 
both kinases [37, 38]. Interestingly we observed only an increase in RyR2 
phosphorylation at the CaMKII site at 2 weeks, where proarrhythmogenic Ca2+ waves 
were more frequent (Fig. 6G). This may reflect the acute arrhythmic phase of 
anticancer therapy [39]. However, in our in vivo ECG telemetry analyses, we only 
found one Dox treated mice with ventricular extrasystole at 2 weeks after the last 
injection and none on saline treated mice. This may be due to the high resistance to 
arrhythmia of mice. In vitro, [17] upon acute Dox treatment, CaMKII activation and 
RyR2 phosphorylation have been reported. We found that the RyR2 phosphorylation 
at the CaMKII site (S2814) is maintained for at least 2 weeks after the treatment. 
CaMKII activation at earlier point could be due to oxidation 
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[37], as Dox activate ROS [16] or by Ca2+ itself, as Dox directly activates RyR2 [19]. This 
increase in RyR2 phosphorylation at the CaMKII site is transient: at 6 weeks is not 
significant anymore and completely normal at 15 weeks. Thus at 6 weeks, the 
normalization of RyR2 expression and phosphorylation levels, together with reduced 
PLB expression, can underlie this compensatory state. Nevertheless, this compensation 
has its limits, as at 15 weeks there is a further decrease in SERCA expression and 
enhanced of the RyR2 phosphorylation at the PKA site.
In summary, we found that mice treated with Dox at therapeutic like doses, significantly 
induce a clear cardiotoxic effect 15 weeks after treatment. Heart dysfunction at 15 weeks 
post- treatment may be due, at least in part, to a depressed [Ca2+]i transient. The latter 
may be the reflect of a low SR Ca2+ load due to depression in SERCA expression and 
enhanced Ca2+ leak through RyRs, which appear early in absence of clear cardiac 
function alterations, before to be transiently compensated. Our work points out that Ca2+ 
homeostasis alterations contribute to Dox induced cardiomyopathy, in addition to the 
classical and current dogma linking cardiotoxicity to the sole cell death. Moreover, this 
cardiac dysfunction seems to be specific to Dox-induced toxicity, being different from 
cardiac dysfunction from other etiologies, notably by the lack of hypertrophy and AP 
alterations. 
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Figure legends
Figure 1: Doxorubicin induces a cardiotoxicity in mice at 15 weeks after the last 
injection.
Representative M mode echocardiograms of mice from saline and doxorubicin treatment 
groups (A). Ejection fraction (B), fractional release (C) and end diastolic diameter (D) of 
treated mice at 2, 6 and 15 weeks after the last injection. The number of treated mice 
are indicated in the column of the B graph. E. Representative left ventricular cardiac 
tissue sections after Picrosirius red illustrating the interstitial collagen 15 weeks after the 
last saline (left) or Dox (right) injection, and the corresponding fibrosis quantification 
(N=4 each group). *p<0.05 compared with control.
Figure 2. Evolution of [Ca2+]i transients after chronic Dox treatment. A. 
Representative line scan confocal microscopy images taken from cardiomyocytes at 2 
(left), 6 (middle) and 15 weeks after last saline (top) or Dox (bottom) injection during 
electrical field stimulation at 2 Hz. B. Peak [Ca2+]i transient in ventricular cardiomyocytes 
in saline treated (gray bars, Saline) or Dox treated (blue bars, Dox) at 2, 6 and 15 weeks 
(2w, 6w, 15w) after the last injection, normalized to saline treated mice. Number of cells 
is noted in the bars. C. Normalized decay time constant of the [Ca2+]i transients 
(obtained by fitting the decaying phase to a single exponential). Colors and symbols as 
in B. C. Unloaded cell shortening in cardiomyocytes from each group. *p<0.05.
Figure 3. Action potential duration is unaffected by Dox treatment. Averaged values 
of action potential duration at 20 (APD20%), 50 (APD 50%) and 90 (APD90%) % of 
repolarization in saline (gray bars) and Dox treated mice (blue bars) at 2 weeks (A), 6 
weeks (B) and 15 weeks (C) after the last injection. Labeling as in Fig. 2. Inset 
representative AP traces recorded in saline (black line) or Dox (gray line) treated mice. 
Figure 4. SR Ca2+ load is depressed 15 weeks after the last Dox injection. A. 
Representative line scan images of a cardiac myocyte treated with saline (top) or Dox 
(bottom) at 2 (left), 6 (middle) and 15 (right) weeks after the last injection during field 
stimulation and subsequent caffeine (10mM) rapid application. B. Normalized averaged 
values of peak caffeine evoked [Ca2+]i transients at different times after the last injection. 
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Number of cells is noted in the bars. C. Normalized averaged decay time constant of the 
caffeine-evoked [Ca2+]i transient obtained by fitting the decay phase to a single 
exponential. D. Immunoblots of NCX (left) and normalized level expression of NCX 
protein (right) at 2, 6, and 15 weeks after the last injection. Colors and symbols as in Fig. 
2. *p<0.05 Dox vs. Saline.
Figure 5. Time-dependent modulation of Calcium handling proteins induced by 
Doxorubicin at 2, 6 and 15 weeks after the last injection in vivo Immunoblots 
showing SERCA (A) and its quantification (B) in each group studied. C Examples of 
immunoblots of total and phosphorylated phospholamban. Quantitative protein 
expression of total (D), P-S16- (E) and P-T17 phospholamban (F) from the left ventricle 
of mice injected or not (saline) with Dox at 2, 6 or 15 weeks after the last treatment. 
Numbers of mice are indicated as above. Immunoblots were quantified and normalized 
to  expression and internal control. Data are mean±SEM and are expressed as 
percentage of the control value (saline-injected mice). *p<0.05, ** p<0.01, ***p<0.001 
compared to saline.
Fig. 6. Spontaneous Ca2+ release in enhanced early and late after Dox treatment. A. 
Representative line-scan images showing individual Ca2+ sparks in cardiac cells isolated 
2 (left), 6 (middle) or 15 (right) weeks after the last saline (top) or Dox (bottom) injection. 
B. Normalized Ca2+ sparks frequency in each experimental group. Number of cells is 
noted in each bar. 
C. Immunoblots against total or phosphorylated RyR2 and  expression from 
cardiac myocytes isolated from mice hearts at 2, 6 and 15 weeks after the last saline or 
Dox injection. Quantification of total RyR2 (D), P-S2808-RyR2 (E) and P-S2814-RyR2 
(F) at different times after the last injection. G.  Ca2+ wave frequency in each cell group. 
Insert a line scan confocal image showing a Ca2+ wave. H. ECG recorded in a mouse 2 
weeks after the last Dox injection showing ventricular ectopy (VE). Color and symbols as 
in Fig. 2. 
Supp. Fig. 1. Morphometric characteristics of mice at different times after the last 
Dox injection.
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A. Body weight of mice treated with doxorubicin or vehicle (Saline solution NaCl 0.9%). 
B: Ratio of heart weight/tibia length of treated mice at 2, 6 and 15 weeks after the last 
injection. The number of treated mice are indicated in the column of the graph. Results 
are expressed as percentage of control mice values. No significant difference of the ratio 
heart weight/tibia length between control and doxorubicin-treated mice after 2, 6 or 15 
weeks have been observed. C. Hematoxylin/eosin stain of mice left ventricular section at 
2 (left), 6 (middle) or 15 (right) weeks after the last saline (top) or Dox (bottom) injection. 
No significant structural alterations or inflammation have been detected.
Supp. Fig. S2. Ca2+ sparks characteristics in cardiomcyocytes isolated from mice 
2, 6 or 15 weeks after the last Dox or saline injection. A. Ca2+ spark amplitude, 
expressed in peak F/F0 where F is the fluorescence and F0 the diastolic fluorescence. B 
Duration at half the maximum, and C Width at half maximum. N here indicates the Ca2+ 
sparks number. ** p<0.01, ***p<0.001 compared to saline.
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